TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00601757

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Postpartum Prevention Program (PPP)
Description: PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced care as usual (ECU)
Description: ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
Study: NCT04421092

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior laryngeal nerve block
Description: Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
Study: NCT05010057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrants (NZBC)
Description: NZBC capsules containing anthocyanin-rich blackcurrant extract
Study: NCT04421092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior laryngeal nerve block
Description: Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo (saline)
Description: Superior laryngeal nerve block using 1mL of saline as the injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of steroid-lidocaine mixture
Description: Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
Study: NCT04625062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-based treatment
Description: Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
Study: NCT00746330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MFF)
Description: Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MFF)
Description: Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
Study: NCT03827018

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mavrilimumab
Description: 1 mL of 150 mg in a pre-filled syringe

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL of placebo in a pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Study: NCT02524184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 100 mg per day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an identical placebo per day for 7 days
Study: NCT00986024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: carried out 3 times per week for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: carried out 3 times per week for 12 weeks
Study: NCT05342649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: P-CTG
Description: soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG
Description: soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
Study: NCT01081392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 20mcg sd inhaled via nebulizer, 3 periods
Study: NCT01636284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594 recombinant vaccina GM-CSF
Description: Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
Study: NCT00004466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00949533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
Study: NCT02190500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Stroke Unit Management
Description: Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
Study: NCT00156195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10 mg Tablet, oral Daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 months
Study: NCT03202394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIO-11006
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer.
Study: NCT01597817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chitosan coated textile
Description: chitosan coated cotton long sleeved shirts and pants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chitosan free cotton long sleeved t-shirts and pants.
Description: chitosan free cotton long sleeved shirts and pants.
Study: NCT00560417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Protamine Suspension
Description: Administered subcutaneously once a day at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered subcutaneously once a day at bedtime
Study: NCT00622726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
Study: NCT01274442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample will be taken to identify relevant genetic polymorphisms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample will be taken to identify relevant genetic polymorphisms.
Study: NCT01935687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of instrumented wheel
Description: Using of instrumented wheel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of ergometer roller
Description: Using of ergometer roller
Study: NCT02307721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Description: Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular naloxone
Description: Administer 2 mL, dose intramuscular naloxone 0,8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Unidose
Description: This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
Study: NCT02772965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Description: 1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Study: NCT02410902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study: NCT01477151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volatile anesthetic
Description: The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration.
Study: NCT00622726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laser for ROP
Description: Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
Study: NCT01477151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volatile anesthetic
Description: The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration.
Study: NCT03087825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation without inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: preoxygenation without inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation with inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: preoxygenation with inward leak
Description: breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
Study: NCT01714050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy (LT)
Description: SunRay (SunBox Company, Gaithersburg, MD)
Study: NCT04341259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
Study: NCT03483311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy before and after NB-UVB phototherapy
Description: skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy before and after NB-UVB phototherapy
Description: skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
Study: NCT03404401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: Oral bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol bowel preparation
Description: Oral bowel preparation
Study: NCT00890552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle
Study: NCT00746330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MFF)
Description: Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg pMDI (F12M)
Description: Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg pMDI (F12M)
Description: Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg pMDI (F12M)
Description: Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg pMDI (F12M)
Description: Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg DPI (F12D)
Description: Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg DPI (F12D)
Description: Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg DPI (F12D)
Description: Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg DPI (F12D)
Description: Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12D
Description: Placebo to formoterol fumarate DPI delivered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12D
Description: Placebo to formoterol fumarate DPI delivered via DPI
Study: NCT00890552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle
Study: NCT00746330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12D
Description: Placebo to formoterol fumarate DPI delivered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12D
Description: Placebo to formoterol fumarate DPI delivered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12M/MFF
Description: Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
Study: NCT03914118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative modafinil + postoperative placebo
Description: 200 mg modafinil pre-operatively and placebo immediately post-operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative modafinil + postoperative modafinil
Description: 200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative placebo + postoperative placebo
Description: Placebo pre-operatively and placebo immediately post-operatively.
Study: NCT02843659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04339569

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical analysis
Description: 3D analysis of landing manoeuvres.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical analysis
Description: 3D analysis of landing manoeuvres.

Intervention type: OTHER
Intervention: Fatigue protocol
Description: A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.

Intervention type: OTHER
Intervention: Fatigue protocol
Description: A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
Study: NCT00746330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to F12M/MFF
Description: Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI